JP2021530525A - ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド - Google Patents
ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド Download PDFInfo
- Publication number
- JP2021530525A JP2021530525A JP2021502574A JP2021502574A JP2021530525A JP 2021530525 A JP2021530525 A JP 2021530525A JP 2021502574 A JP2021502574 A JP 2021502574A JP 2021502574 A JP2021502574 A JP 2021502574A JP 2021530525 A JP2021530525 A JP 2021530525A
- Authority
- JP
- Japan
- Prior art keywords
- oxazepan
- carboxamide
- ethyl
- cyano
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1ccc(C[C@@](C(O)=O)N*)cc1 Chemical compound *c1ccc(C[C@@](C(O)=O)N*)cc1 0.000 description 2
- AEXFXNFMSAAELR-RXVVDRJESA-N CN(c(cc(cc1)-c2ccc(C[C@@H](C#N)NC([C@H]3OCCCNC3)=O)cc2)c1O1)C1=O Chemical compound CN(c(cc(cc1)-c2ccc(C[C@@H](C#N)NC([C@H]3OCCCNC3)=O)cc2)c1O1)C1=O AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699494P | 2018-07-17 | 2018-07-17 | |
| US62/699,494 | 2018-07-17 | ||
| PCT/US2019/042021 WO2020018547A1 (en) | 2018-07-17 | 2019-07-16 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530525A true JP2021530525A (ja) | 2021-11-11 |
| JP2021530525A5 JP2021530525A5 (cg-RX-API-DMAC7.html) | 2022-07-20 |
Family
ID=69164738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502574A Pending JP2021530525A (ja) | 2018-07-17 | 2019-07-16 | ループス腎炎を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11998553B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3823627A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021530525A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210032431A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019306532A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3106269A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020018547A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (cg-RX-API-DMAC7.html) | 2014-01-24 | 2018-02-24 | ||
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| WO2022166721A1 (zh) * | 2021-02-05 | 2022-08-11 | 南京明德新药研发有限公司 | 含1,4-氧杂氮杂环庚烷的并环类衍生物 |
| TW202404960A (zh) * | 2022-06-07 | 2024-02-01 | 大陸商瑞石生物醫藥有限公司 | 苯并[c]色滿化合物的多晶型及其製備方法和用途 |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性dpp1阻害剤及びその用途 |
| WO2025162472A1 (en) | 2024-01-31 | 2025-08-07 | Insmed Incorporated | Linear dipeptidyl peptidase 1 inhibitors and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017503832A (ja) * | 2014-01-24 | 2017-02-02 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | ジペプチジルペプチダーゼ1阻害剤としての(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド |
| US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
| JP2021512904A (ja) * | 2018-02-07 | 2021-05-20 | インスメッド インコーポレイテッド | Anca関連血管炎の治療のためのある種の(2s)−n−[(1s)−1−シアノ−2−フェニル]−1,4−オキサゼパン−2−カルボキサミド |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| DE60131423T2 (de) | 2000-09-08 | 2009-03-19 | Prozymex A/S | Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| PL370766A1 (en) | 2001-12-04 | 2005-05-30 | F.Hoffmann-La Roche Ag | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| WO2004106289A1 (en) | 2003-05-30 | 2004-12-09 | Prozymex A/S | Protease inhibitors |
| WO2004110988A1 (en) | 2003-06-18 | 2004-12-23 | Prozymex A/S | Protease inhibitors |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| EP1745292A2 (en) * | 2004-04-28 | 2007-01-24 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| BRPI0508063A (pt) | 2004-06-29 | 2007-07-17 | Nycomed Danmark Aps | processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica |
| JP5704785B2 (ja) | 2004-07-19 | 2015-04-22 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫抑制のためのflt3阻害剤 |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| KR20100060004A (ko) | 2007-09-25 | 2010-06-04 | 노파르티스 아게 | 에어로졸화된 반코마이신과 같은 의약에 의한 폐 질병의 치료 |
| US7902181B2 (en) | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| PT2413913T (pt) | 2009-04-01 | 2022-06-09 | Bial Portela & Ca Sa | Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar |
| EA201190235A1 (ru) | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| JP6479476B2 (ja) | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | SykチロシンキナーゼインヒビターおよびGCN2セリンキナーゼインヒビターとしての8−置換2−アミノー[1,2,4]トリアゾロ[1,5−A]ピラジン類 |
| CA2870527A1 (en) | 2012-04-17 | 2013-10-24 | Astellas Pharma Inc. | Nitrogenated bicyclic aromatic heterocyclic compound |
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| EP2775304A1 (en) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| EP2970252B1 (en) | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| EA029052B1 (ru) | 2013-03-14 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с |
| JP6441830B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換2−アザ−ビシクロ[2.2.1]ヘプタン−3−カルボン酸(シアノ−メチル)−アミド阻害剤 |
| JP6437929B2 (ja) | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換二環式1−カルボン酸(ベンジル−シアノ−メチル)−アミド阻害剤 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| WO2015027039A1 (en) | 2013-08-22 | 2015-02-26 | Emory University | Devices and methods related to airway inflammation |
| CN105612149A (zh) | 2013-09-09 | 2016-05-25 | 普罗技迈克斯公司 | 作为二肽基肽酶i抑制剂的肽基腈化合物 |
| WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| CN106456552A (zh) | 2014-04-10 | 2017-02-22 | 诺华股份有限公司 | S1p调节剂的立即释放剂量方案 |
| MX384843B (es) | 2014-05-15 | 2025-03-14 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
| CN107075557B (zh) | 2014-05-30 | 2021-07-06 | 香港大学 | 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物 |
| WO2016016242A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim International Gmbh | Substituted oxetanes and their use as inhibitors of cathepsin c |
| HUE047208T2 (hu) | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
| MX370366B (es) | 2014-11-14 | 2019-12-11 | Boehringer Ingelheim Int | Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4). |
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| PT3758708T (pt) | 2018-03-01 | 2025-02-13 | Astrazeneca Ab | Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida |
| WO2020018551A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| EP4252844A3 (en) | 2019-04-17 | 2023-12-06 | Azora Therapeutics, Inc. | Topical compositions and methods for treating inflammatory skin diseases |
| AU2020289560A1 (en) | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| US20240226112A1 (en) | 2021-04-29 | 2024-07-11 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| CN118159525A (zh) | 2021-10-29 | 2024-06-07 | 英斯梅德股份有限公司 | 用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺 |
| JP2025508359A (ja) | 2022-02-16 | 2025-03-26 | インスメッド インコーポレイテッド | 化膿性汗腺炎を治療するためのある特定のn-(1-シアノ-2-フェニルエチル)-1,4-オキサゼパン-2-カルボキサミド |
-
2019
- 2019-07-16 CA CA3106269A patent/CA3106269A1/en active Pending
- 2019-07-16 US US17/260,606 patent/US11998553B2/en active Active
- 2019-07-16 JP JP2021502574A patent/JP2021530525A/ja active Pending
- 2019-07-16 EP EP19837016.5A patent/EP3823627A4/en not_active Withdrawn
- 2019-07-16 AU AU2019306532A patent/AU2019306532A1/en not_active Abandoned
- 2019-07-16 KR KR1020217004073A patent/KR20210032431A/ko not_active Ceased
- 2019-07-16 WO PCT/US2019/042021 patent/WO2020018547A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017503832A (ja) * | 2014-01-24 | 2017-02-02 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | ジペプチジルペプチダーゼ1阻害剤としての(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド |
| US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
| JP2021512904A (ja) * | 2018-02-07 | 2021-05-20 | インスメッド インコーポレイテッド | Anca関連血管炎の治療のためのある種の(2s)−n−[(1s)−1−シアノ−2−フェニル]−1,4−オキサゼパン−2−カルボキサミド |
Non-Patent Citations (3)
| Title |
|---|
| DOYLE, KEVIN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, JPN6023018039, 2016, pages 9457 - 9472, ISSN: 0005211143 * |
| SCHREIBER, ADRIAN ET AL., JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 23, JPN6023018040, 2012, pages 470 - 482, ISSN: 0005211144 * |
| 廣村桂樹, 池内秀和, 加家壁健, 野島美久, 日本腎臓学会誌, vol. 56, no. 4, JPN6023018041, 2014, pages 510 - 517, ISSN: 0005211145 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3823627A1 (en) | 2021-05-26 |
| US11998553B2 (en) | 2024-06-04 |
| CA3106269A1 (en) | 2020-01-23 |
| US20210322438A1 (en) | 2021-10-21 |
| KR20210032431A (ko) | 2021-03-24 |
| AU2019306532A1 (en) | 2021-03-04 |
| EP3823627A4 (en) | 2022-04-20 |
| WO2020018547A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11998553B2 (en) | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| WO2021228161A1 (zh) | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 | |
| ES2813368T3 (es) | Nuevos moduladores de receptores de fosfato de esfingosina | |
| JP7390415B2 (ja) | ニューロキニン-1受容体アンタゴニストとしての化合物およびその使用 | |
| BR112021008516A2 (pt) | Inibidores de quinase 7 dependente de ciclina (cdk 7) | |
| CA3140485A1 (en) | Egfr inhibitor for the treatment of cancer | |
| JP2022531609A (ja) | 新規メチルキナゾリノン誘導体 | |
| JP2021530513A (ja) | 炎症性腸疾患を処置するための特定の(2s)−n−[(1s)−1−シアノ−2−フェニルエチル]−1,4−オキサゼパン−2−カルボキサミド | |
| WO2021098859A1 (zh) | 氮杂七元环类抑制剂及其制备方法和应用 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| JP5484726B2 (ja) | Gsk−3阻害剤 | |
| WO2013068554A1 (en) | New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities | |
| AU2019217870A1 (en) | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides | |
| CN103857392A (zh) | 用于治疗增生性疾病的2-甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合 | |
| WO2013068552A1 (en) | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | |
| JP7737991B2 (ja) | Egfr阻害剤 | |
| WO2022140516A1 (en) | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease | |
| WO2025149082A1 (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| WO2018186366A1 (ja) | 新規サイクリン依存性キナーゼ8及び/又は19阻害剤 | |
| TW201302736A (zh) | 組織蛋白酶(Cathepsin)C抑制劑 | |
| JP2020505363A (ja) | オキサジン誘導体を含む医薬組成物、およびこの医薬組成物のアルツハイマー病の処置または予防での使用 | |
| WO2022143695A1 (zh) | 磺酰胺类抑制剂及其制备方法和应用 | |
| ES2262515T3 (es) | R-hidroxinefazodona. | |
| JP2009517483A (ja) | 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体 | |
| WO2026021499A1 (zh) | 卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220711 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231205 |